drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified; CAR-DNT cells)
drug_description
Off-the-shelf, lentiviral gene-modified double-negative T cells expressing an anti-CD19 chimeric antigen receptor to deplete CD19+ B-lineage cells in refractory SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf, lentiviral-engineered double-negative T cells (CD3+CD4−CD8−) expressing an anti-CD19 chimeric antigen receptor bind CD19 on B-lineage cells and trigger T-cell cytotoxic effector functions (e.g., perforin/granzyme, death receptor pathways), depleting CD19+ B cells and plasmablast precursors to reduce autoantibody production and B cell–driven inflammation in SLE.
drug_name
RJMty19 (CD19-CAR-DNT cells)
nct_id_drug_ref
NCT06340490